GLSI

Greenwich LifeSciences, Inc. NASDAQ Listed Sep 25, 2020

Healthcare ·Biotechnology ·US · greenwichlifesciences.com

$23.67

Mkt Cap $327.9M

52w Low $7.78 60.4% of range 52w High $34.10

50d MA $25.05 200d MA $17.21

P/E (TTM) -19.6x

EV/EBITDA -9.0x

P/B 121.7x

Debt/Equity 0.0x

ROE -790.5%

P/FCF -20.1x

RSI (14) —

ATR (14) —

Beta 1.53

50d MA $25.05

200d MA $17.21

Avg Volume 182.5K

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

SIC Code

2834

CIK (SEC)

1799788

Phone

832 819 3232

Building 14 · Stafford, TX 77477 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Nov 14, 2025	AMC	-0.30	-0.30	+0.0%	8.32	+0.8%	-1.1%	-1.0%	-2.3%	-1.9%	-2.0%	—
Aug 14, 2025	AMC	-0.24	-0.30	-25.0%	12.08	+1.0%	+0.7%	-0.6%	-5.0%	-1.2%	-1.9%	—
May 20, 2025	AMC	-0.24	-0.25	-4.2%	10.30	-2.9%	-5.5%	-4.9%	-4.8%	-3.1%	-5.6%	—
Apr 15, 2025	AMC	-0.21	-0.61	-190.5%	8.95	-0.7%	-1.2%	+0.0%	+4.4%	+7.6%	+10.1%	—
Nov 14, 2024	AMC	-0.21	-0.20	+4.8%	13.59	+5.3%	-7.6%	-9.0%	-6.0%	-5.4%	-4.6%	—
Aug 14, 2024	AMC	-0.20	-0.20	+0.0%	12.99	+3.9%	+4.5%	+7.1%	+9.2%	+6.4%	+13.9%	—
May 20, 2024	AMC	-0.20	-0.19	+5.0%	13.08	+2.0%	+3.5%	+3.2%	+0.0%	+2.4%	+0.8%	—
Apr 15, 2024	AMC	-0.20	-0.21	-5.0%	14.26	-3.4%	+1.1%	-8.5%	-9.6%	-15.4%	-11.0%	—
Oct 19, 2023	AMC	-0.22	-0.19	+13.6%	8.27	-0.3%	+0.1%	-6.0%	-0.8%	-3.9%	+0.0%	—
Aug 21, 2023	AMC	-0.23	-0.13	+43.5%	10.15	-5.2%	-1.5%	-2.2%	-5.8%	-8.5%	-9.3%	—
May 22, 2023	AMC	-0.23	-0.17	+26.1%	11.80	+1.4%	-1.7%	-4.0%	-8.5%	-8.2%	-7.5%	—
Mar 31, 2023	AMC	-0.18	-0.22	-22.2%	13.79	+1.7%	-4.3%	-6.8%	-7.5%	-4.8%	-8.3%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Dec 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$24.78	$25.93	+4.6%	-11.5%	-15.2%	-21.4%	-14.4%	-17.2%
Apr 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.95	$9.05	+1.1%	+4.4%	+7.6%	+10.1%	+16.6%	+11.5%
Feb 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.23	$12.04	-1.6%	-1.8%	-2.1%	+0.6%	+1.2%	+2.5%
Aug 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.14	$14.63	+3.5%	+5.2%	+3.4%	-1.1%	-3.3%	+0.7%
May 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.54	$13.86	+2.4%	-0.3%	-3.4%	-1.0%	-2.6%	-2.7%
Feb 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.50	$12.43	-0.6%	-3.4%	-2.7%	+4.0%	+3.7%	+0.6%
Feb 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.24	$11.40	+1.4%	+15.1%	+17.1%	+19.2%	+15.0%	+7.5%
Apr 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.13	$13.10	-0.2%	-3.7%	-7.0%	-12.0%	-8.8%	-10.1%
Sep 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$40.02	$42.00	+4.9%	+9.3%	+11.1%	+9.8%	+11.9%	+9.6%
Jan 27	Aegis Capital	Maintains	Buy → Buy	—	$36.54	$36.65	+0.3%	-6.4%	-6.4%	+2.6%	-1.7%	-0.3%
Jan 26	Aegis Capital	Maintains	Buy → Buy	—	$36.16	$36.25	+0.2%	+1.1%	-5.4%	-5.4%	+3.7%	-0.7%

Data updated apr 25, 2026 11:42am · Source: massive.com